Botulinum toxin injections do not help with male pattern baldness.
October 2025 in “Journal of Cosmetic Dermatology” Botulinum toxin Type A helps reduce hypertrophic scars and is generally safe.
June 2017 in “Journal of the American Academy of Dermatology” Tofacitinib is effective and safe for treating severe alopecia areata and related conditions.
February 2024 in “PloS one” Tofacitinib and adalimumab are promising treatments for cicatricial alopecia with few side effects.
3 citations
,
September 2021 in “Journal of Investigative Dermatology” Baricitinib was more effective than a placebo in regrowing hair in adults with alopecia areata after 36 weeks.
28 citations
,
December 2017 in “Journal of Investigative Dermatology Symposium Proceedings” Tofacitinib shows promise for treating severe hair loss in adults and teens, with many experiencing regrowth, but hair loss returns when treatment stops.
9 citations
,
July 2024 in “Toxins” OnabotulinumtoxinA is used to treat wrinkles, pain, sweating, hair loss, and more by temporarily paralyzing muscles and affecting pain pathways.
Baricitinib helped treat a man's beard hair loss when steroids didn't work.
48 citations
,
November 2017 in “Journal of the American Academy of Dermatology” Tofacitinib 2% ointment helped hair regrow in 3 out of 10 patients with alopecia areata, but caused side effects like scalp irritation and raised cholesterol in some.
Reducing the dose of Baricitinib to 2mg still helped over half of the patients with severe scalp alopecia maintain their hair regrowth after two years.
July 2025 in “Pakistan Journal of Intensive Care Medicine” Clobetasol propionate 0.05% ointment is more effective than tacrolimus 0.1% ointment for treating alopecia areata.
2 citations
,
April 2024 in “Dermatology Practical & Conceptual” Tofacitinib and baricitinib are effective and safe for treating severe alopecia areata, especially in younger people.
1 citations
,
September 2023 in “Dermatology and Therapy” Baricitinib helps improve hair growth in severe alopecia, with better results in less severe cases and higher doses working faster.
Botulinum toxin-A may increase hair growth and reduce hair loss in men with baldness, and injecting near blood vessels can improve pain relief and last longer.
August 2024 in “JAMA Dermatology” Continuous baricitinib is needed to keep hair regrowth in severe alopecia areata.
February 2011 in “Annales de dermatologie et de vénéréologie” Tofacitinib shows promise for treating severe alopecia areata with good safety and effectiveness.
10 citations
,
October 2014 in “Plastic & Reconstructive Surgery Global Open” Botulinum toxin type A injections improved hair growth and scalp health in a woman with radiation-induced hair loss.
February 2024 in “Journal of the European Academy of Dermatology and Venereology” Baricitinib is effective and safe for long-term use in severe alopecia areata, improving hair regrowth and quality of life with few side effects.
4 citations
,
September 2022 in “Journal of The American Academy of Dermatology” Baricitinib was effective in regrowing hair in patients with different levels of alopecia areata severity.
May 2024 in “Journal of cosmetic dermatology” Tofacitinib is an effective and safe treatment for alopecia areata.
July 2021 in “Journal of dermatology & dermatologic surgery” IMTA can help regrow hair in severe alopecia areata when JAK inhibitors don't work well.
5 citations
,
January 2009 Betamethasone is more effective than Tacrolimus and soft paraffin for hair regrowth in patchy alopecia areata.
9 citations
,
August 2018 in “JAAD Case Reports” Tofacitinib can temporarily improve hair growth in alopecia universalis, but its effectiveness may decrease over time.
June 2025 in “International Journal of Science and Research (IJSR)” Tofacitinib effectively promotes hair regrowth in alopecia areata with minimal side effects.
January 2023 in “The Egyptian Journal of Hospital Medicine” Botulinum toxin type A is a safe and effective treatment for male pattern baldness.
September 2023 in “Journal of The American Academy of Dermatology” Reducing the dose of Baricitinib to 2mg led to a loss of hair regrowth benefits in nearly half of the patients by Week-104.
November 2023 in “Annales de dermatologie et de vénéréologie, FMC” Baricitinib effectively treats severe alopecia for up to 104 weeks.
April 2023 in “Journal of Investigative Dermatology” Baricitinib at 2mg and 4mg doses improved work productivity and reduced costs for adults with atopic dermatitis.
June 2023 in “British Journal of Dermatology” Baricitinib was effective in treating severe and very severe alopecia areata after 52 weeks.
1 citations
,
August 2021 in “Journal of The American Academy of Dermatology” Baricitinib was effective in treating both early and late onset alopecia areata.